Immix Biopharma, a leader in AL Amyloidosis, priced a registered offering of 19,117,646 shares of common stock at $5.10/share, totaling $100 million. Proceeds will fund NXC-201 development. Morgan Stanley is the book-running manager. The offering, closing on December 9, 2025, will meet operational needs into mid-2027. NXC-201, a CAR-T cell therapy, is in U.S. multi-center study NEXICART-2 for AL Amyloidosis. Forward-looking statements highlight risks and uncertainties. Contact Mike Moyer at LifeSci Advisors or email [email protected] for more information.

Read more at GlobeNewswire: Immix Biopharma Announces Pricing of Upsized $100 Million